Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

The Tobacco Epidemic

Editor(s): Loddenkemper R. (Berlin) 
Kreuter M. (Heidelberg) 
Cover

Chapter 17

Smoking and Mental Health Problems

Caillé S.a, b · Baker A.L.c, d · Todd J.c, d · Turner A.c-f · Dayas C.V.c, d

Author affiliations

aInstitut de Neurosciences Cognitives et Intégratives d'Aquitaine (INCIA), Université de Bordeaux, and bCentre National de la Recherche Scientifique, UMR5287 INCIA, Bordeaux, France; cHunter Medical Research Institute, Newcastle, N.S.W., dPriority Research Centre for Translational Neuroscience and Mental Health, University of Newcastle, Callaghan, N.S.W., eIMPACT Strategic Research Centre, School of Medicine, Deakin University, Geelong, Vic., and fDepartment of Psychiatry, The University of Melbourne, Parkville, Vic., Australia

Related Articles for ""

Loddenkemper R, Kreuter M (eds): The Tobacco Epidemic, ed 2, rev. and ext. Prog Respir Res. Basel, Karger, 2015, vol 42, pp 199-209

Do you have an account?

Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information












By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.


I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Chapter 17

Published online: March 24, 2015
Cover Date: 2015

Number of Print Pages: 11
Number of Figures: 1
Number of Tables: 1

ISBN: 978-3-318-02656-6 (Print)
eISBN: 978-3-318-02657-3 (Online)

Abstract

Patients with mental illness have greater rates of smoking during their lifetime and experience severe social, health and psychological disadvantages, and stigma. This chapter begins by providing a brief update on the neurobiology of nicotine addiction and we present evidence that an imbalance in the brain reward and aversion systems, and specific nicotinic acetylcholine receptor subtypes expressed in these pathways, may lead to dependence. Then, in a special case review, we highlight recent advances regarding the knowledge on the association between nicotine dependence and schizophrenia. Further understanding these mechanistic links, including nicotine-induced improvements in cognitive deficits, might provide new insights into improving smoking cessation success in people diagnosed with schizophrenia. Additionally, we discuss data indicating that smoking cessation does not worsen mental health symptoms or increase other drug and alcohol use. Indeed, smoking cessation interventions should be available within mental health and substance use treatment settings. Treatments for nicotine addiction include psychological interventions and pharmacological agents such as nicotine replacement therapies (e.g. gums and lozenges) or medications such as the partial agonist varenicline. Importantly, the outcomes for smokers with mental illness are enhanced when these approaches are combined and may need to be administered over the long term.

© 2015 S. Karger AG, Basel


References

  1. Lasser K, Boyd J, Woolhandler S, Himmelstein DU, McCormick D, Bor DH: Smoking and mental illness: a population-based prevalence study. JAMA 2000;284:2606-2610.
  2. Williams JM, Ziedonis D: Addressing tobacco among individuals with a mental illness or an addiction. Addict Behav 2004;29:1067-1083.
  3. Degenhardt L, Hall W: The Relationship between Tobacco Use, Substance Use Disorders and Mental Disorders: Results from the National Survey of Mental Health and Well-Being. Sydney, National Drug & Alcohol Research Centre, UNSW, 1999.
  4. Cook B, Wayne G, Kafali E, Liu Z, Shu C, Flores M: Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA 2014;311:172-182.
  5. Siru R, Hulse GK, Tait RJ: Assessing motivation to quit smoking in people with mental illness: a review. Addiction 2009;104:719-733.
  6. Banham L, Gilbody S: Smoking cessation in severe mental illness: what works? Addiction 2010;105:1176-1189.
  7. Hitsman B, Moss TG, Montoya ID, George TP: Treatment of tobacco dependence in mental health and addictive disorders. Can J Psychiatry 2009;54:368-378.
    External Resources
  8. Prochaska JJ, Delucchi K, Hall SM: A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol 2004;72:1144-1156.
  9. Okoli CTC, Khara M, Procyshyn RM, Johnson JL, Barr AM, Greaves L: Smoking cessation interventions among individuals in methadone maintenance: a brief review. J Subst Abuse Treat 2010;38:191-199.
  10. Castagnoli K, Steyn S, Magnin G, Van Der Schyf C, Fourie I, Khalil A, et al: Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase. Neurotox Res 2002;4:151-160.
  11. Corrigall W, Coen K: Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology 1989;99:473-478.
  12. Koob GF, Le Moal M: Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 2008;363:3113-3123.
  13. Caille S, Clemens K, Stinus L, Cador M: Modeling nicotine addiction in rats. Methods Mol Biol 2012;829:243-256.
  14. Edwards S, Koob GF: Escalation of drug self-administration as a hallmark of persistent addiction liability. Behav Pharmacol 2013;24:356-362.
  15. Ahmed SH, Kenny PJ, Koob GF, Markou A: Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci 2002;5:625-626.
  16. Changeux J-P: Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat Rev Neurosci 2010;11:389-401.
  17. Bossert J, Marchant N, Calu D, Shaham Y: The reinstatement model of drug relapse: recent neurobiological findings, emerging research topics, and translational research. Psychopharmacology 2013;229:453-476.
  18. Clemens K, Caillé S, Cador M: The effects of response operandum and prior food training on intravenous nicotine self-administration in rats. Psychopharmacology 2010;211:43-54.
  19. Koob GF: A role for brain stress systems in addiction. Neuron 2008;59:11-34.
  20. Picciotto MR, Mineur YS: Molecules and circuits involved in nicotine addiction: the many faces of smoking. Neuropharmacology 2014;76(pt B):545-553.
  21. Exley R, Maubourguet N, David V, Eddine R, Evrard A, Pons S, et al: Distinct contributions of nicotinic acetylcholine receptor subunit α4 and subunit α6 to the reinforcing effects of nicotine. Proc Natl Acad Sci 2011;108:7577-7582.
  22. Orejarena MJ, Herrera-Solís A, Pons S, Maskos U, Maldonado R, Robledo P: Selective re-expression of β2 nicotinic acetylcholine receptor subunits in the ventral tegmental area of the mouse restores intravenous nicotine self-administration. Neuropharmacology 2012;63:235-241.
  23. Fowler CD, Lu Q, Johnson PM, Marks MJ, Kenny PJ: Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011;471:597-601.
  24. Pons S, Fattore L, Cossu G, Tolu S, Porcu E, McIntosh J, et al: Crucial role of α4 and α6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci 2008;28:12318-12327.
  25. Caillé S, Guillem K, Cador M, Manzoni O, Georges F: Voluntary nicotine consumption triggers in vivo potentiation of cortical excitatory drives to midbrain dopaminergic neurons. J Neurosci 2009;29:10410-10415.
  26. Reisiger A-R, Kaufling J, Manzoni O, Cador M, Georges F, Caillé S: Nicotine self-administration induces CB1-dependent LTP in the bed nucleus of the stria terminalis. J Neurosci 2014;34:4285-4292.
  27. Hikosaka O: The habenula: from stress evasion to value-based decision-making. Nat Rev Neurosci 2010;11:503-513.
  28. McCallum SE, Cowe MA, Lewis SW, Glick SD: α3β4 nicotinic acetylcholine receptors in the medial habenula modulate the mesolimbic dopaminergic response to acute nicotine in vivo. Neuropharmacology 2012;63:434-440.
  29. Frahm S, Ślimak MA, Ferrarese L, Santos-Torres J, Antolin-Fontes B, Auer S, et al: Aversion to nicotine is regulated by the balanced activity of β4 and α5 nicotinic receptor subunits in the medial habenula. Neuron 2011;70:522-535.
  30. Görlich A, Antolin-Fontes B, Ables JL, Frahm S, Ślimak MA, Dougherty JD, et al: Reexposure to nicotine during withdrawal increases the pacemaking activity of cholinergic habenular neurons. Proc Natl Acad Sci U S A 2013;110:17077-17082.
  31. Bierut L, Stitzel J, Wang J, Hinrichs A, Grucza R, Xuei X, et al: Variants in nicotinic receptors and risk for nicotine dependence. Am J Psychiatry 2008;165:1163-1171.
  32. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, Zaridze D, et al: A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008;452:633-637.
  33. Saccone NL, Schwantes-An TH, Wang JC, Grucza RA, Breslau N, Hatsukami D, et al: Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans. Genes Brain Behav 2010;9:741-750.
  34. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, et al: A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008;452:638-642.
  35. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, et al: Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A 2005;102:19168-19173.
  36. Harris GC, Wimmer M, Aston-Jones G: A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005;437:556-559.
  37. Hollander JA, Lu Q, Cameron MD, Kamenecka TM, Kenny PJ: Insular hypocretin transmission regulates nicotine reward. Proc Natl Acad Sci U S A 2008;105:19480-19485.
  38. Corrigall WA: Hypocretin mechanisms in nicotine addiction: evidence and speculation. Psychopharmacology 2009;206:23-37.
  39. Yeoh JW, Campbell EJ, James MH, Graham BA, Dayas CV: Orexin antagonists for neuropsychiatric disease: progress and potential pitfalls. Front Neurosci 2014;8:36.
  40. Plaza-Zabala A, Martín-García E, de Lecea L, Maldonado R, Berrendero F: Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. J Neurosci 2010;30:2300-2310.
  41. James MH, Charnley JL, Levi EM, Jones E, Yeoh JW, Smith DW, et al: Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical to regulating cue-induced reinstatement of cocaine-seeking. Int J Neuropsychopharmacol 2011;14:684-690.
  42. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL, et al: Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007;6:746-762.
  43. Simonnet A, Cador M, Caille S: Nicotine reinforcement is reduced by cannabinoid CB1 receptor blockade in the ventral tegmental area. Addict Biol 2013;18:930-936.
  44. Markou A: Metabotropic glutamate receptor antagonists: novel therapeutics for nicotine dependence and depression? Biol Psychiatry 2007;61:17-22.
  45. Carlsson A, Carlsson ML: A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin Neurosci 2006;8:137-142.
    External Resources
  46. Kumari V, Postma P: Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 2005;29:1021-1034.
  47. Chambers RA: A nicotine challenge to the self-medication hypothesis in a neurodevelopmental animal model of schizophrenia. J Dual Diagn 2009;5:139-148.
  48. Smith GN, Wong H, MacEwan GW, Kopala LC, Ehmann TS, Thornton AE, et al: Predictors of starting to smoke cigarettes in patients with first episode psychosis. Schizophr Res 2009;108:258-264.
  49. Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL: The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr Res 1997;25:21-31.
  50. Hong LE, Schroeder M, Ross TJ, Buchholz B, Salmeron BJ, Wonodi I, et al: Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr Bull 2011;37:416-425.
  51. Sacco KA, Termine A, Seyal A, et al: Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia: involvement of nicotinic receptor mechanisms. Arch Gen Psychiatry 2005;62:649-659.
  52. Smith RC, Singh A, Infante M, Khandat A, Kloos A: Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology 2002;27:479-497.
  53. Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP, et al: The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 2007;33:480-490.
  54. Depatie L, O'Driscoll GA, Holahan A-LV, Atkinson V, Thavundayil JX, Kin NNY, et al: Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study. Neuropsychopharmacology 2002;27:1056-1070.
  55. George TP, Vessicchio JC, Termine A, Sahady DM, Head CA, Pepper WT, et al: Effects of smoking abstinence on visuospatial working memory function in schizophrenia. Neuropsychopharmacology 2002;26:75-85.
  56. Adler LE, Hoffer LD, Wiser A, Freedman R: Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 1993;150:1856-1861.
  57. Turetsky B, Dent G, Jaeger J, Zukin S: P50 amplitude reduction: a nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients. Psychopharmacology 2012;221:39-52.
  58. Hong LE, Wonodi I, Lewis J, Thaker GK: Nicotine effect on prepulse inhibition and prepulse facilitation in schizophrenia patients. Neuropsychopharmacology 2007;33:2167-2174.
  59. George TP, Termine A, Sacco KA, Allen TM, Reutenauer E, Vessicchio JC, et al: A preliminary study of the effects of cigarette smoking on prepulse inhibition in schizophrenia: involvement of nicotinic receptor mechanisms. Schizophr Res 2006;87:307-315.
  60. Gurpegui M, Martínez-Ortega JM, Jurado D, Aguilar MC, Diaz FJ, de Leon J: Subjective effects and the main reason for smoking in outpatients with schizophrenia: a case-control study. Compr Psychiatry 2007;48:186-191.
  61. Hofmann SG, Asnaani A, Vonk IJ, Sawyer AT, Fang A: The efficacy of cognitive behavioral therapy: a review of meta-analyses. Cogn Ther Res 2012;36:427-440.
  62. Brown RA, Kahler CW, Niaura R, Abrams DB, Sales SD, Ramsey SE, et al: Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol 2001;69:471.
  63. Hettema J, Steele J, Miller WR: Motivational interviewing. Annu Rev Clin Psychol 2005;1:91-111.
  64. Etter J-F: Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006;166:1553-1559.
  65. Asevedo E, Mendes AC, Berk M, Brietzke E: Systematic review of N-acetylcysteine in the treatment of addictions. Rev Brasil Psiquiatr 2014;36:168-175.
  66. Berk M, Malhi GS, Gray LJ, Dean OM: The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 2013;34:167-177.
  67. Castle D, Baker AL, Richmond R, Filia SL, Harris D, Pirola-Merlo AJ: Varenicline plus healthy lifestyle intervention for smoking cessation in psychotic disorders. Ann Clin Psychiatry 2012;24:285-291.
    External Resources
  68. Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, et al: Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 2014;311:145-154.
  69. Hitsman B, Papandonatos GD, McChargue DE, DeMott A, Herrera MJ, Spring B, et al: Past major depression and smoking cessation outcome: a systematic review and meta-analysis update. Addiction 2013;108:294-306.
  70. Weinberger AH, Mazure CM, Morlett A, McKee SA: Two decades of smoking cessation treatment research on smokers with depression: 1990-2010. Nicotine Tob Res 2013;15:1014-1031.
  71. Shakeshaft A, Bowman J, Sanson-Fisher R: Community-based drug and alcohol counselling: who attends and why? Drug Alcohol Rev 2002;21:153-162.
  72. Richter KP, Gibson CA, Ahluwalia JS, Schmelzle KH: Tobacco use and quit attempts among methadone maintenance clients. Am J Public Health 2001;91:296-299.
  73. John U, Hill A, Rumpf H-J, Hapke U, Meyer C: Alcohol high risk drinking, abuse and dependence among tobacco smoking medical care patients and the general population. Drug Alcohol Depend 2003;69:189-195.
  74. Clarke J, Stein M, McGarry K, Gogineni A: Interest in smoking cessation among injection drug users. Am J Addict 2001;10:159-166.
  75. Batel P, Pessione F, Maitre C, Rueff B: Relationship between alcohol and tobacco dependencies among alcoholics who smoke. Addiction 1995;90:977-980.
  76. Hurt R, Offord K, Croghan I: Mortality following inpatient addictions treatment: role of tobacco use in a community-based cohort. JAMA 1996;275:1097-1103.
  77. Baker A, Ivers RG, Bowman J, Butler T, Kay-Lambki, FJ, Wye P, Walsh RA, Pulver LJ, Richmond R, Belcher J, Wilhelm K, Wodak A: Where there's smoke,there's fire: high prevalence of smoking among some sub-populations and recommendations for intervention. Drug and Alcohol Rev 2006;25:85-96.

Article / Publication Details

First-Page Preview
Abstract of Chapter 17

Published online: March 24, 2015
Cover Date: 2015

Number of Print Pages: 11
Number of Figures: 1
Number of Tables: 1

ISBN: 978-3-318-02656-6 (Print)
eISBN: 978-3-318-02657-3 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.